Spinal orexin A attenuates opioid-induced mechanical hypersensitivity in the rat
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Repeated administration of opioid analgesics for pain treatment can produce paradoxical hyperalgesia via peripheral and/or central mechanisms. Thus, this study investigated whether spinally (centrally) administered orexin A attenuates opioid-induced hyperalgesia (OIH). Methods: [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO), a selective μ-opioid receptor agonist, was used to induce mechanical hypersensitivity and was administered intradermally (4 times, 1-hour intervals) on the rat hind paw dorsum. To determine whether post- or pretreatments with spinal orexin A, dynorphin A, and antidynorphin A were effective in OIH, the drugs were injected through an intrathecal catheter whose tip was positioned dorsally at the L3 segment of the spinal cord (5 μg for all). Mechanical hypersensitivity was assessed using von Frey monofilaments. Results: Repeated intradermal injections of DAMGO resulted in mechanical hypersensitivity in rats, lasting more than 8 days. Although the first intrathecal treatment of orexin A on the 6th day after DAMGO exposure did not show any significant effect on the mechanical threshold, the second (on the 8th day) significantly attenuated the DAMGO-induced mechanical hypersensitivity, which disappeared when the type 1 orexin receptor (OX1R) was blocked. However, intrathecal administration of dynorphin or an anti-dynorphin antibody (dynorphin antagonists) had no effect on DAMGO-induced hypersensitivity. Lastly, pretreatment with orexin A, dynorphin, or anti-dynorphin did not prevent DAMGO-induced mechanical hypersensitivity. Conclusions: Spinal orexin A attenuates mechanical hyperalgesia induced by repetitive intradermal injections of DAMGO through OX1R. These data suggest that OIH can be potentially treated by activating the orexin A-OX1R pathway in the spinal dorsal horn.
Abstract
Background: Repeated administration of opioid analgesics for pain treatment can produce paradoxical hyperalgesia via peripheral and/or central mechanisms. Thus, this study investigated whether spinally (centrally) administered orexin A attenuates opioid-induced hyperalgesia (OIH). Methods: [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO), a selective μ-opioid receptor agonist, was used to induce mechanical hypersensitivity and was administered intradermally (4 times, 1-hour intervals) on the rat hind paw dorsum. To determine whether post- or pretreatments with spinal orexin A, dynorphin A, and antidynorphin A were effective in OIH, the drugs were injected through an intrathecal catheter whose tip was positioned dorsally at the L3 segment of the spinal cord (5 μg for all). Mechanical hypersensitivity was assessed using von Frey monofilaments. Results: Repeated intradermal injections of DAMGO resulted in mechanical hypersensitivity in rats, lasting more than 8 days. Although the first intrathecal treatment of orexin A on the 6th day after DAMGO exposure did not show any significant effect on the mechanical threshold, the second (on the 8th day) significantly attenuated the DAMGO-induced mechanical hypersensitivity, which disappeared when the type 1 orexin receptor (OX1R) was blocked. However, intrathecal administration of dynorphin or an anti-dynorphin antibody (dynorphin antagonists) had no effect on DAMGO-induced hypersensitivity. Lastly, pretreatment with orexin A, dynorphin, or anti-dynorphin did not prevent DAMGO-induced mechanical hypersensitivity. Conclusions: Spinal orexin A attenuates mechanical hyperalgesia induced by repetitive intradermal injections of DAMGO through OX1R. These data suggest that OIH can be potentially treated by activating the orexin A-OX1R pathway in the spinal dorsal horn.
참고문헌 (39)
- Kim SH, "Intraoperative use of remifentanil and opioid induced hyperalgesia", acute opioid tolerance : systematic review, 2014, pp.5, 108~
- Lee M, "A comprehensive review of opioid-induced hyperalgesia", Pain Physician, 14, pp.145~161 (2011)
- Mao J, "Opioid-induced abnormal pain sensitivity : implications in clinical opioid therapy", Pain, 100, pp.213~217 (2002)
- Mao J, "Chronic morphine induces downregulation of spinal glutamate transporters : implications in morphine tolerance and abnormal pain sensitivity", J Neurosci, 22, pp.8312~8323 (2002)
- Scholz J, "Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury", J Neurosci, 25, pp.7317~7323 (2005)
- Vanderah TW, "Mechanisms of opioid-induced pain and antinociceptive tolerance : descending facilitation and spinal dynorphin", Pain, 92, pp.5~9 (2001)
- Gardell LR, "Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers", J Neurosci, 22, pp.6747~6755 (2002)
- Yamamoto Y, "Down regulation of the prepro-orexin gene expression in genetically obese mice", Brain Res Mol Brain Res, 65, pp.14~22 (1999)
- Lin L, "The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin(orexin)receptor 2 gene", Cell, 98, pp.365~376 (1999)
- Date Y, "Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems", Proc Natl Acad Sci U S A, 96, pp.748~753 (1999)
- Jeon Y, "Orexin-A modulates excitatory synaptic transmission and neuronal excitability in the spinal cord substantia gelatinosa", Neurosci Lett, 604, pp.128~133 (2015)
- Chen J, "Induction of homosynaptic long-term depression at spinal synapses of sensory a delta-fibers requires activation of metabotropic glutamate receptors", Neuroscience, 98, pp.141~148 (2000)
- Park KB, "Orexin receptors mediate long-term depression of excitatory synaptic transmission in the spinal cord dorsal horn", Neurosci Lett, 660, pp.12~16 (2017)
- Niknia S, "Neuroprotective and antihyperalgesic effects of orexin-A in rats with painful diabetic neuropathy", Neuropeptides, 73, pp.34~40 (2019)
- Yamamoto T, "Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model", Neurosci Lett, 347, pp.183~186 (2003)
- Risold PY, "Preprohypocretin(orexin)and prolactin-like immunoreactivity are coexpressed by neurons of the rat lateral hypothalamic area", Neurosci Lett, 259, pp.153~156 (1999)
- Araldi D, "Repeated mu-opioid exposure induces a novel form of the hyperalgesic priming model for transition to chronic pain", J Neurosci, 35, pp.12502~12517 (2015)
- Yaksh TL, "Chronic catheterization of the spinal subarachnoid space", Physiol Behav, 17, pp.1031~1036 (1976)
- Deuis JR, "Methods used to evaluate pain behaviors in rodents", Front Mol Neurosci, 10, pp.284~ (2017)
- Charan J, "How to calculate sample size in animal studies", J Pharmacol Pharmacother, 4, pp.303~306 (2013)
- Wang Z, "Pronociceptive actions of dynorphin maintain chronic neuropathic pain", J Neurosci, 21, pp.1779~1786 (2001)
- Vanderah TW, "Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats : blockade by MK-801 but not naloxone", Pain, 68, pp.275~281 (1996)
- Mobarakeh JI, "Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B(hypocretin-1 and-2)in mice", Peptides, 26, pp.767~777 (2005)
- Cheng JK, "Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain", J Pharmacol Exp Ther, 307, pp.1065~1071 (2003)
- Araldi D, "Hyperalgesic priming(type II)induced by repeated opioid exposure : maintenance mechanisms", Pain, 158, pp.1204~1216 (2017)
- de Lecea L, "The hypocretins : hypothalamus-specific peptides with neuroexcitatory activity", Proc Natl Acad Sci U S A, 95, pp.322~327 (1998)
- Sakurai T, "Orexins and orexin receptors : a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior", Cell, 92, pp.573~585 (1998)
- Cutler DJ, "Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord", Peptides, 20, pp.1455~1470 (1999)
- van den Pol AN, "Hypothalamic hypocretin(orexin) : robust innervation of the spinal cord", J Neurosci, 19, pp.3171~3182 (1999)
- Bingham S, "Orexin-A, an hypothalamic peptide with analgesic properties", Pain, 92, pp.81~90 (2001)
- Hervieu GJ, "Gene expression and protein distribution of the orexin-1receptor in the rat brain and spinal cord", Neuroscience, 103, pp.777~797 (2001)
- i in dosal root ganglion neuron of rat segmental spinal nerve ligation model, "Jpn Pharmacol Ther", 2014, 723~734
- Zhou HY, "Opioid-induced longterm potentiation in the spinal cord is a presynaptic event", J Neurosci, 30, pp.4460~4466 (2010)
- Watanabe S, "Persistent pain and stress activate pain-inhibitory orexin pathways", Neuroreport, 16, pp.5~8 (2005)
- Azhdari-Zarmehri H, "Orexin-A modulates firing of rat rostral ventromedial medulla neurons : an in vitro study", Cell J, 17, pp.163~170 (2015)
- Bannister K, "Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord", Neuropharmacology, 85, pp.375~383 (2014)
- Kajander KC, "Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy", Peptides, 11, pp.719~728 (1990)
- Vanderah TW, "Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance", J Neurosci, 20, pp.7074~7079 (2000)
- Yamamoto T, "Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test", Br J Pharmacol, 137, pp.170~176 (2002)